Nephrology Dialysis Transplantation Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure

Abstract. A^A^dimethyl-L-arginine (asymmetric dimethyl-L-arginine; ADMA) and N]^ dimethyl-L-arginine (symmetric dimethyl-L-arginine; SDMA) are naturally occurring analogues of L-arginine, the substrate for nitric oxide (NO) synthesis. ADMA is a potent inhibitor of NO synthesis, and accumulates in the plasma of patients with renal failure. However the precise concentration of ADMA and SDMA in renal patients is still controversial. This study was performed to measure plasma ADMA and SDMA concentrations by two different HPLC techniques in nine healthy controls and 10 uraemic subjects, and to investigate the effects of haemodialysis. In controls, the mean (±SEM) plasma concentrations of ADMA and SDMA were 0.36 + 0.09 and 0.39 + 0.05 umol/1 respectively, yielding an ADMA/SDMA ratio of 1.2 + 0.17. In uraemic patients, the plasma concentrations of ADMA and SDMA were 0.9 + 0.08 umol/1 (P < 0.001 compared to controls) and 3.4 + 0.3 umol/1 (P<0.001 compared to controls) with an ADMA/SDMA ratio of 0.27 ±0.015 (P<0.00l). In the course of one4h haemodialysis session, ADMA concentrations decreased from 0.99 + 0.13 to 0.77 + 0.3 umol/1 and SDMA concentrations from 3.38 + 0.44 to 2.27 + 0.21 umol/1. The plasma ADMA/creatinine ratio tended to increase from 1.26 + 0.20 x 10~ to 2.01 ±0.41 x 10~. It is concluded that there is a modest (3-fold) but definite increase in plasma ADMA concentration in uraemic patients compared to controls. SDMA accumulates to a greater degree (8-fold increase) and more closely parallels creatinine concentration than ADMA. The change in the ADMA/SDMA ratio is not accounted for by greater renal or dialysis clearance of ADMA, and, even though alternative explanations are not excluded, greater metabolism of ADMA than SDMA is the most likely explanation. Although small in magnitude, the increase in ADMA concentration might be biologically significant. Correspondence and offprint requests to: R. J. MacAllister, Department of Pharmacology and Clinical Pharmacology, St Georges Hospital Medical School, London, UK.

[1]  R. Coppo,et al.  Enhanced production of nitric oxide by blood-dialysis membrane interaction. , 1995, Journal of the American Society of Nephrology : JASN.

[2]  C. Tetta,et al.  Regulation of nitric oxide synthesis in uraemia. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  S. Klahr,et al.  Role of arginine in health and in renal disease. , 1994, The American journal of physiology.

[4]  T. Saruta,et al.  Nitric oxide increases renal blood flow by interacting with the sympathetic nervous system. , 1994, Hypertension.

[5]  R. Macallister,et al.  Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis , 1994, British journal of pharmacology.

[6]  R. Cohen,et al.  Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  S. Moncada,et al.  Effects of a nitric oxide synthase inhibitor in humans with septic shock. , 1994, Cardiovascular research.

[8]  G. Remuzzi,et al.  Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. , 1993, Kidney international.

[9]  F. Salazar,et al.  Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. , 1992, Hypertension.

[10]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[11]  M. Aldegunde,et al.  High-performance liquid chromatographic separation with electrochemical detection of amino acids focusing on neurochemical application. , 1992, Analytical biochemistry.